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Abstract - Dexmedetomidine (DEX) is a relatively recent a2-adrenergic agonist which provides sedation, 
anxiolysis and analgesia with much less respiratory depression than other sedatives. These characteristics have 
implemented the use of the drug in the ICUs in order to achieve the target of a “arousable sedation”, thanks to 
its significant manageability. Its sedative-analgesic properties are also particularly suitable for use in burn 
ICUs, both adult and pediatric, which is why the current Guidelines have recognized a central role in the 
management of these categories of patients. Finally, DEX has showed significant anti-inflammatory effect 
both in animal models and in preliminary clinical trials, reducing vasopressor requirements and main 
mediators levels of the systemic inflammatory response involved in sepsis and similar processes, suggesting 
its use for improved outcome in ICU septic patients. 
 




Dexmedetomidine (DEX) is a novel α2-adrenergic 
agonist that provides sedation, anxiolysis and analgesia 
with much less respiratory depression than other sedatives 
1. It is a selective α2-adrenoceptor agonist similar to 
Clonidine of the imidazole subclass 2.  
The mechanism of sedation by α2-agonists is thought 
to occur via activation of presynaptic receptors in the 
reticular formation, inhibiting the release of 
norepinephrine, primarily at the locus ceruleus. The 
analgesic effects and potentiation of opioid-induced 
analgesia result from the activation of α2-adrenergic 
receptors in the dorsal horn of the spinal cord and 
inhibition of substance-P release 3. Thus, these drugs 
have been noted to reduce the need for narcotics. The end-
organ effects are mediated via postsynaptic α2-adrenergic 
receptors and subsequent activation of a pertussis toxin-
sensitive guanine nucleotide regulatory protein (G protein) 
3. 
The bradycardia associated with DEX is caused by 
activation of receptors in the medullary vasomotor center, 
reducing norepinephrine with resultant central 
sympatholytic effect: decreased heart rate and blood 
pressure 3. Respiratory drive appears to be maintained 
during DEX administration. 
DEX exhibits a higher specificity for α2-receptors and 
has a shorter half-life than Clonidine (2−3 vs 12–24 
hours) 3. Its elimination half-life is approximately 2 h 
after a rapid distribution phase of about 6 min, with 
mainly renal elimination (95%). The drug is metabolized 
in the liver via N-glucuronidation, N-methylation, and 
cytochrome P450, then excreted primarily in the urine. 
There are no active or toxic metabolites. It can be 
antagonized if needed by administration of atipamezole 
4. 
Contraindications include hypersensitivity to DEX or 
any component, as well as use outside of the intensive 
care setting. Adverse reactions are primarily cardiogenic, 
with bradycardia and sinus arrest associated with rapid 
intravenous administration. Hypotension is also a possible 
adverse effect. There is also concern for withdrawal 
symptoms similar to Clonidine if used for prolonged 
periods or abruptly discontinued 5. 
DEX produces “arousable sedation” and analgesia 
with prevention of recall and memory at higher doses 3. 
DEX sedation exhibits properties similar to natural sleep, 
specifically simulating nonrapid eye movement sleep. 
The stated uses are:  
1) sedation of initially intubated and mechanically 
ventilated patients during treatment in an intensive care 
unit (ICU);  
2) sedation prior to and/or during surgical or other 
procedures of nonintubated patients;  
3) premedication prior to anesthesia induction;  
4) treatment of shivering;  
5) premedication to attenuate the cardiostimulatory 
and postanesthetic delirium of ketamine.  
DEX is approved by the FDA for use in people aged 
≥18 years 2.  
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II. ROLE IN ICU 
 
A large body of recent work supports its favorable 
profile in improving outcome from ICU delirium 6, for 
opioid, benzodiazepine, and alcohol withdrawal 7, as 
well as for sedation during monitored anesthesia care and 
regional anesthesia 8. 
The goal of sedation in the ICU is a patient who is 
calm, possibly lightly asleep, but easily arousable. Many 
drugs have been used, including ketamine, inhalational 
anesthetics, tranquilizers, and benzodiazepines 9,10. 
Continuous midazolam infusion is commonly used in 
ICUs, but often patients develop a tolerance to the drug 
11. This can lead to increasing doses of midazolam as 
well as inadequate sedation 11,12,13. Other significant 
physiological effects at therapeutic doses include a slight 
reduction in heart rate, systemic vascular resistance, and a 
small reduction in tidal volume with a compensatory 
increased respiratory rate. Potential complications thus 
include hypotension, respiratory depression, and 
oversedation 13.  
A prospective, double-blind, randomized trial in 68 
medical centers in five countries found that DEX and 
midazolam produced equivalent sedation in adult ICU 
patients. During the study, DEX was used for a shorter 
time period because of more rapid extubation. Patients 
treated with DEX were found to have significant decrease 
in delirium as well. The main complication was 
bradycardia (42.2% of patients), while 4.9% of patients 
required an intervention, either titration of DEX or 
atropine. Alternatively, there was a higher percentage of 
patients who had tachycardia and hypertension in the 
midazolam group. There were no episodes of rebound 
hypertension or tachycardia in the DEX group 14. 
Benzodiazepines disrupt the normal electro-
encephalographic patterns of sleep, and these effects may 
be responsible for the delirium seen in the ICU setting. 
Because DEX allows patients to get a more healthy sleep 
pattern, they may theoretically be able to avoid ICU 
delirium and the increased complications therein3. Each 
additional day of delirium increases the risk of prolonged 
hospitalization by 20% and increases the likelihood of a 
poor functional status at 3 and 6 months 14. 
In a recent (2010) meta-analysis on the analgesic and 
sedative effects of DEX on patients requiring mechanical 
ventilation in the ICU, Tan and Ho showed that DEX may 
reduce the length of stay of some ICU patients but had no 
effect on days of ventilation 15.  
An updated meta-analysis of all RCTs on DEX was 
recently made by Pasin et al. 16 in order to compare the 
drug to alternative systems used in ICU settings, 
evaluating some parameters such as time to extubation, 
ICU stay and survival. 27 manuscripts were admitted to 
the study, including 3648 (Dex group: 1870; controls: 
1778) heterogeneous patients, especially in ICU settings: 
general ICU (13 trials), cardiac surgery ICU (10 trials), 
major non-cardiac surgery ICU (4 Trials) and admission to 
the ICU after cesarean section-eclampsia (1 trial). In 18 
trials a loading dose between 0.1 to 6 mcg/kg preceded the 
continuous infusion, this one the only technique used in 6 
trials and ranged between 0.1 to 2.5 mcg/kg/h. In one trial 
only the loading dose was used and one trial gave no 
details. 
DEX was compared to propofol, midazolam, placebo, 
morphine, haloperidol and lorazepam.  
The main results of this meta-analysis showed that 
DEX group is associated with a reduction in ICU stay, 
time of extubation, rescue dose of sedative or analgesic 
drugs; on the other hand, with an increased risk of 
bradycardia and hypotension, but without significant 
worsening of mortality 16. 
 
 
III. ROLE IN BURN ICU - PATHOPHYSIOLOGY 
OF PAIN IN BURN PATIENTS 
 
The pain is a fundamental aspect in the management 
of burn patients 17. In fact, the prolonged exposure to 
painful stimuli, directly related to the burned surface, 
causes centralization of pain and persistent pain 18,19. 
The incidence of chronic burn pain is related to the levels 
and duration of acute pain 19.  
Acute pain evoked by thermal burns causes 
stimulation of the skin nociceptors and is transmitted to 
the cerebral cortex through three pathways 20,21, while 
in the periphery neurotransmitter release, axon reflex, 
redness, swelling, tenderness and release of inflammatory 
response mediators occur. These phenomena increase the 
sensitivity of nociceptors, causing the so-called primary 
hyperalgesia 18,21,22; furthermore, the continuous 
stimulation of nociceptive afferent fibers determines 
excitability of dorsal horn and hypersensitivity of  
surrounded undamaged skin, the so-called secondary 
hyperalgesia 18,21, that may cause chronic pain 22,23. 
In burn patients experience pain depends on the 
quality of pain 18. The background pain 20,24 is 
exacerbated by different types of pain, characteristically of 
high intensity and short duration, the procedural pain 
20,24, the unpredictable breakthrough pain and the 
postoperative pain 18,20,24,25. Tissue regeneration is 
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associated with patient discomfort (tingling and itching 
sensation) 22. After the wounds have healed, burn 
patients could experience “neuropathic pain”. The 
International Association for the Study of Pain defines it 
as “pain initiated or caused by a primary lesion or 
dysfunction in the nervous system” 26.  It has been 
described as burning, “stabbing, shooting, pinsand needles, 
and electric shock-like sensations” 27. 
The most beneficial effects of DEX seem to be 
apparent in the perioperative phase, as documented by 
Scheinin et al, who described that DEX reduced the 
requirement of opioids perioperatively in the recovery 
room 28; the analgesic requirements of burn patients are 
different compared to the general population due to higher 
sensitivity and adapting pain levels caused by the high 
frequency of surgical procedures or dressing changes. 
DEX showed a major contribution to patients sedation and 
well being in the setting of the burn ICU. 
       In a study designed to compare analgesic efficacy and 
side effects of oral dexmedetomidine and ketamine in 
adults for burn wound dressing,  Kundra et al. 29 divided 
randomly into 2 groups sixty healthy adults with thermal 
burns: the first group received 5 mg/kg ketamine and the 
second group 4 mcg/kg oral DEX.  
Even if the mean VAS score was significantly 
reduced from baseline in both the groups at all time points 
(P < 0.05), in the first group pain relief (overall mean VAS 
2.6 ± 0.6 cm) was significantly better when compared to 
second group (overall mean VAS 3.8 ± 0.8 cm), the 
related patients were significantly more sedated (median 
3) when compared to second group (median 2, P < 0.05) 
and the main complications observed were delirium and 
excessive salivation. Finally more patients preferred 
ketamine (63.3%) than dexmedetomidine (36.7%), P < 
0.05.  
Although the dex has sedative and analgesic 
properties, it is less effective than ketamine for acute 
situations management in burns ICU 29. 
Ketamine is a rapid, safe and effective anaesthetic 
agent during burns debridement and dressing changes, 
with few contraindications. Propofol, used for its 
favourable pharmacokinetics, lacks the analgesic property 
intrinsic to ketamine, whereby fentanyl is added to 
compliment its analgesic property.  
Given the pharmacological properties of these drugs, 
we can expect that concomitant dexmedetomidine use may 
reduce the requirement of propofol and ketamine, with 
faster postoperative recovery and more stable 
intraoperative haemodynamics. 
For this purpose, sixty adult patients posted for 
elective debridement and dressing included in the study of 
Ravipati et al. 30 were divided into two groups: thirty 
patients received intramuscular DEX, 1 μg/kg, 1 h before 
shifting to the operation theatre, while the other thirty did 
not. A titrated infusion of propofol and ketamine followed 
to get a score of Ramsay Sedation Scale (RSS) six in all 
patients. Intraoperatively haemodynamic parameters were 
recorded at regular intervals of 5, 15, 30, 45, and 60 min. 
At the end of the surgical procedure, the drug infusion 
was discontinued; the total drug consumption and the 
recovery time (i.e. the time from discontinuation of 
infusion of the study drug and achievement of RSS score 
of 3) was noted. 
The mean doses of ketamine and propofol used in 
DEX group (100.5 ± 17.58 mg and 127.7 ± 15.47mg) were 
significantly less than in control group (231.5 ± 60.39 mg 
and 254 ± 59.22 mg respectively). Time to recovery was 
significantly lower in the control group (9.57 ± 1.50 min 
vs. 11.53 ± 2.56 min) 
The choice of the dex dose used in the study comes 
from the evaluation that most previous investigations have 
proven the cardiovascular depressive effects of i.m. DEX 
at a dose of 2.5 μg/kg, which increases the incidence of 
hypotension and bradycardia, whilst Virkkila et al. 31 
has shown that i.m. DEX 1 μg/kg produces sedation with 
minimal haemodynamic side effects when given as 
premedication. 
Adding DEX with ketamine shows the great 
advantage of balancing haemodynamic and adverse effects 
of each other: DEX decreases the incidence of tachycardia, 
hypertension, salivation, and emergence phenomena from 
ketamine, while ketamine prevents bradycardia and 
hypotension of DEX. Furthermore ketamine speeds the 
onset time of sedation, tipically slow for i.m. DEX 30. 
DEX (1 μg/kg i.m. dose) is a good anaesthetic 
adjuvant that decreases the requirement of propofol and 
ketamine during burns debridement and dressings, reduces 
sympathoadrenal response, provides hemodynamic 
stability and adequate levels of analgesia, and finally has 
an excellent recovery profile. 
 
 
IV. ROLE IN PEDIATRIC ICU 
Dex has been used as an off-label drug for sedation of 
children in the intensive care unit 32,33; the preliminary 
experience in burned pediatric patients did suggest opioid 
sparing effects 34. 
Sedation in children can be even more difficult to 
achieve because of parental separation, stranger fear, 
incomprehension, and degree of perceived situational 
control.  
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Hsin Lin et al. 35 describe the dosing, safety, and 
efficacy of DEX for sustained sedation in intubated 
pediatric burn patients, treated between 2005 and 2008. 
Patients served as their own controls using the time 
periods when they received sedatives other than DEX. 
Eleven patients with 17 DEX treatment courses were 
identified. The median patient age was 7 years (range 1.6–
17 years), and median burn size was 30.5% TBSA (range 
6–59%). Patients were ventilated for a median of 9 days 
(range 4–46 days). The median initial dose of DEX was 
0.39 gamma/kg/hr (range 0.10–1.16 /gamma /kg/hr), with 
a median infusion dose of 0.57 gamma/kg/hr (range 0.11–
1.17 gamma/kg/hr) and median treatment duration of 40 
hours (range 1–356 hours). None of the patients received 
DEX loading dose. Patients achieved more appropriate 
Riker scores while treated with DEX than while being 
treated with other sedatives (3.8 vs 3.3, P 0.003). The 
incidence of hypotension and/or bradycardia while on 
DEX was not greater than when it was not being used. 
Median length of hospital stay was 49 days (range 7–118 
days). 
DEX seemed to be safe and effective for sedation of 
pediatric burn patients on mechanical ventilation 35. 
A prospective, randomized study of DEX vs mid-
azolam in mechanically ventilated infants and children 
found that DEX at a dose of 0.25 mcg/kg/hr was 
equivalent to midazolam at 0.22 mg/kg/hr. DEX at 0.5 
mcg/kg/hr was found to be superior to midazolam for 
sedation. It had fewer morphine bolus doses, decreased 24-
hour morphine needs and decreased remarks of inadequate 
sedation 32. 
The hemodynamic consequences and the 
sympatholytic effects 36-38 of DEX administration, at 
higher doses in pediatric burn patients, have been 
systemically studied with prospective preliminary study by 
examining the hemodynamic changes during bolus and 
continuous infusion of Dex administered in sequence 36. 
Eight intubated patients with ≥20 to 79% TBSA 
received a 1.0 μg/kg bolus of Dex followed by an 
ascending dose infusion protocol (0.7–2.5 μg/kg/hr), with 
each dose administered for 15 minutes. Significant 
hypotension and decrease in heart rate were registered, but 
no bradycardia (HR < 60) or heart blocks were observed. 
In three patients the bolus dose of Dex decreased MAP to 
<50 mmHg; three patients received the highest infusion 
dose of Dex (2.5 μg/kg/hr), whereas in 2 patients the 
infusion was stopped due to persistent hypotension (MAP 
< 50 mm Hg). These data indicate that in critically injured 
pediatric burn patients a bolus dose of Dex (1.0 μg/kg for 
10 minutes) and high infusion rates may require 
countermeasures (fluid resuscitation or vasopressor 
support) to maintain normotension 36.  
 
 
V. HAEMODYNAMIC CHANGES IN BURN 
PATIENTS 
 
The hypotension observed in burned patients is a 
frequent phenomenon. The pathophysiology of burn injury 
involves a persistent circulating levels of epinephrine, 
norepinephrine, and dopamine 39,40 and an increased 
renin-angiotensin activity, responsible for inducing 
hypertension or maintening normotension even during 
relative hypovolemia 41-43. In these patients, the 
sympatholysis  and  the MAP decrease  produced by Dex 
can occur more easily. 
The hypotensive response to sedative drugs, like 
morphine and midazolam, is well documented and 
mediated by central and peripheral mechanisms 44,45, 
also in burned patients. Indeed, a 24-hour resuscitation 
volume of 4 mg/kg percent burn is applied by the original 
Parkland formula.  
Recognition of increased pain scores in posttraumatic 
stress disorders 46-48 and consequent liberal sedation 
policy of burn caregivers needed an increased intravenous 
fluid requirements 49,50.  
Decreasing morphine and midazolam doses, or 
volume/ pressor support prior to Dex initiation, might 
prevent drops in blood pressure 36. Finally the opioid-
sparing effects of Dex requires to assess the pretreatment 
volume status and to evaluate rescue measures to support 
the hemodynamic changes 36.  
Walker et al. 12 conducted a retrospective chart 
review of 65 pediatric burn patients (42 boys, 23 girls) in 
the ICU who received DEX infusion because of failure to 
achieve adequate sedation with their standard regimen of 
opioids and benzodiazepines at Shriners Hospital for 
Children, Cincinnati. 
The average duration of DEX was 11 days (range: 2–
50), with a mean DEX dose of 0.5 mcg/kg/hr. With DEX 
titration, all patients were rated ‘‘adequately sedated,’’ 
even though all were sedation failures with opioids and 
benzodiazepines. Eleven of 42 patients receiving 
ventilatory support were extubated while on DEX 
infusion, and no patient showed evidence of DEX induced 
respiratory depression. Infusions were weaned over the 
course of treatment without evidence of rebound 
hypertension or withdrawal, indicating that the longterm 
use of DEX may be safe. No tachyphylaxis was noted 
12. 
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VI. ROLE OF DEX IN ACTUAL GUIDELINES 
 
A very variable tolerance of sedative drugs in some 
patient populations needs to have multiple agents available 
for management of patients in ICU. This makes it difficult 
to apply the findings of randomized controlled trials in 
clinical practice and to evaluate real effectiveness of 
changes in this context 51. 
Over the last years, it is a considerable evidence that 
both choice of a drug and way of its use can significantly 
change patient outcomes. This, in turn, has influenced 
pain, agitation and delirium guidelines 52 that suggest a 
shift in favor of non-benzodiazepine alternatives, as DEX 
or propofol. 
The clinical effectiveness of a sedation protocol 
providing an early use of DEX in place of benzodiazepines  
was assessed in a “before-after” study. Patients required 
continuous sedation (midazolam, propofol or DEX) and 
mechanically ventilated for at least 24 hours in the surgical 
ICU (SICU) or medical ICU (MICU) and included in the 
first group modified the sedation protocol, minimizing use 
of benzodiazepine infusions and favoring early use of 
DEX 51. 
An initial DEX infusion of 0.5 μg/kg/hr (range of 0.2 
to 1.5 μg/kg/hr) without boluses was applied.. In both 
phases, bolus doses of midazolam were administered for 
the management of breakthrough agitation. Propofol and 
midazolam were also allowed in the after phase according 
to physician discretion. A fentanyl infusion and/or boluses 
as needed  was the main treatment of pain in both phases. 
This protocol, that reduces benzodiazepine use and 
targets light sedation, lead to significant improvements in 
the duration of mechanical ventilation and the requirement 
for tracheostomy. In addition, fentanyl infusion for pain, 
used in both group, was significantly reduced in the after 
phase, because of the reduced time on mechanical 
ventilation, the supplementary analgesic properties of 
DEX or an improved ability to assess pain in the after 
phase 51. 
Significant hypotension or bradycardia were not 
observed between groups, and the percentage of patients 
requiring the addition of a vasopressor was lower in the 
after phase. DEX failure occurred in one in four patients, 
because hypotension 51.  
A minimized sedation improves patient outcomes  
53-58. A sedation protocol targeting light sedation as 
standard of care using continuous infusions of DEX 
provides a significant reduction in time on the ventilator, 
but not a statistically significant reduction in ICU length of 
stay 51. 
 
On December 21, 2015 Italian Drug Agency 59 
authorized the insertion of drug dexmedetomidine 
(Dexdor) in the list of drugs distributed in the total load of 
the NHS for the following therapeutic indications: 
procedural analgo-sedation out of the operating room (Not 
Operating Room Anesthesia NORA) in children with 
difficult airway management and in children with seizure 
disorders that should be subjected to diagnostic studies to 
localize epileptic foci, and analgo-sedation in critical 
infants and children in ICU, mechanically ventilated and 
poorly responsive to conventional analgo-sedative 
treatment. 
Inclusion criteria for algo-sedation of critical infants 
and children in ICU are defined: 
- ICU admission 
- mechanical ventilation 
- continuous analgo-sedative treatment for at least five 
days 
- persistent high values of the score evaluation of 
analgo-sedation despite attempts to increase the dosage of 
administered analgesics and sedatives  
- Informed consent by the parents / legal guardians 
Exclusion criteria are: 
- known or suspected hypersensitivity to the drug 
- severe bradycardia 
- severe hypotension 
- ongoing treatment of clonidine or other alpha 
agonist 
 
Under the guidance of the German Society of 
Anaesthesiology and Intensive Care Medicine (DGAI) and 
German Interdisciplinary Association for Intensive Care 
and Emergency Medicine (DIVI), a new version of 
“evidence and consensus based guideline for the 
management of delirium, analgesia, and sedation in 
intensive care medicine” 60 were developed to provide 
practical guidance for the symptom-based prevention, 
diagnostics and therapy of delirium, anxiety, and agitation, 
as well as for the protocol-based analgesia, sedation, and 
sleep management during critical illness. An early 
management of these symptoms improves recovery and 
longterm outcome, while reducing post-intensive-care-unit 
syndrome (PICS) and mortality. 
Aside from an adequate basic level of analgesia, 
additional analgesics (local and systemic) and/or 
procedural sedation may be necessary when performing 
various procedures (e.g. dressing changes). There are 
multimodal concepts for the use of analgesics, adjuvants, 
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and non-pharmacological strategies regarding pain 
management in patients with severe burns 18. Especially 
for analgesia and sedation of burn-injured children, the use 
of standardized protocols and training programs should be 
used 61. 
For analgesia, the continuous intravenous use of 
lidocaine is not recommended 62, while the use of co-
analgesics, such as gabapentin, may be considered 
adjunctively to opioids 63. It is also suggested the use of 
ketamine to reduce secondary hyperalgesia 64,65 and the 
opioid demand 66 of burn patients and the use of  α2-
agonists for sedation, as they have been shown to be more 
effective on burn patients as other drugs (e.g. 
benzodiazepines) 1. 
In burn-injured children, standardized protocols and 
training programs for analgesia and sedation during 
dressing changes are strongly recommended 61.  
The combination of non-pharmacological procedures 
(massage in non-burned areas, hypnosis, and virtual 
reality) with opioids is more effective at alleviating pain 
than a single opioid analgesia 67-69.  
For the of procedural pain, guidelines suggest the use 
of ketamine over opioids 70.  For procedural sedation 
during dressing changes in burned children, the use of 
dexmedetomidine may be considered 2. 
These data recognize a concrete effectiveness of 
dexmedetomidine in the management of the burn patient, 
especially as a fundamental element for the control of 
pain, anxiety, delirium and to achieve an optimal level of 
sedation, correlated to potential improvement of the 
outcome. 
 
VII. DEX IN BURNS AND SEPSIS 
Burns, such as other traumatic injuries, induce global 
changes to the systemic immune response, including 
suppressed immune function and increased susceptibility 
to infection. Moreover,  remote organ injuries affecting 
kidney, lung, gut and bone marrow compartment are often 
associated with burn trauma in human and animal studies. 
This relationship between burn and remote organ injury 
supports the hypothesis that immune suppression may 
facilitate the translocation of gut-derived bacteria and/or 
their products and contribute to the development of 
systemic inflammatory response syndrome, sepsis, and 
multiple organ dysfunction syndrome in critically ill burn 
patients 71 
Progress over the last 50 years has led to a decline in 
mortality from ≈70% to ≈20% in the best series of patients 
with septic shock. In these cases, the mortality appears 
related to multiple organ failure linked to comorbidities 
and/or an intense inflammatory response: shortening the 
period that the subject is exposed to circulatory instability 
may further lower mortality. Treatment aims at 
reestablishing circulation within a “central” compartment 
(i.e., brain, heart, and lung) but fails to reestablish a 
disorganized microcirculation or an adequate response to 
noradrenaline, the most widely used vasopressor 72.  
These evidence indicates a patchy and disperse 
maldistribution of O2 during sepsis, as opposed to an 
inability to utilize O2 73, that is, a cytopathic hypoxia 
74. Increasing the delivery of oxygen to supranormal 
levels may not improve tissue oxygenation if the increased 
O2 supply cannot be properly distributed and early 
treatment aimed at restoring uniform distribution of O2 
may lead to improve outcomes 73. 
In two cases 75, the treatment with the α2-
adrenoceptor agonist, clonidine (1 μg·kg-1·h-1), in addition 
to state-of-the-art treatment, reduced NA requirements in a 
patient presenting with HIV and terminal pulmonary 
sepsis 75 and a neonate presenting with necrotizing 
enterocolitis. In addition, this reduction in requirement for 
NA in rat 76 and sheep 77 experimental models of 
sepsis has been documented, using high and low doses, 
respectively, of the α2-adrenoceptor agonists, clonidine 
and DEX. Furthermore, the pressor responsiveness to a 
noncatecholaminergic vasopressor, angiotensin II, was 
also reduced by clonidine treatment 77. 
One possible mechanism 78 for this effect of α2-
adrenoceptor agonists in sepsis is that, during septic shock, 
as during exercise 79, there is increased sympathetic 
nerve activity and endogenous plasma catecholamines 80-
82 with a downregulation in responsiveness to stimulation 
of α1- and β-adrenoceptors, which may result from reduced 
binding or reduced sensitivity/intracellular coupling. 
Conversely, after lowering plasma catecholamine 
concentrations with pharmacologically evoked α2-
adrenoceptor agonists, as during rest after exercise, the 
downregulation of α1-adrenoceptors is converted to 
upregulation, with an increased pressor response to 
vasopressors. 
The evidence of the anti-inflammatory effect of DEX 
was obtained in several experimental animal models. The 
drug administration in models of induced sepsis, 
inflammation, ischemia-reperfusion injury and trauma 
showed its protective effect, with an overall reduction of 
the inflammatory response, proven by the finding of 
reduced levels of the major mediators of systemic 
inflammation: IL-6 and TNF-α mRNA and respective 
proteins, mRNA for TLR4 and MyD88, NFkB mRNA, 
IFN-γ and IL-4 mRNA, protein HMGB1 83-90. 
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Similar results were obtained in different cell models 
in which the inflammatory response induced by exposure 
to LPS was significantly reduced after DEX incubation 
91-94. 
Finally, the drug effectiveness to modulate the main 
inflammatory mediators levels has been confirmed in 
several clinical trials that investigated the administration 
of dex in patients undergoing surgical procedures 
(hepatectomy, laparoscopic cholecystectomy, abdominal 
surgery, oncologic surgery, cardiopulmonary bypass) or in 
ICU septic patients 95-98. 
These clinical trials suggest that α2-adrenoceptor 
agonists lead to a sympathetic deactivation with a reversal 
of the peripheral microcirculatory shut-down, and reduce 
inflammation and multiple organ failure, proposing an 
effect of DEX on outcomes, including mortality, in sepsis. 
However, evidence-based documentation of the 
effects of α2-agonists is needed in the setting of human 
septic shock, and an end-point on mortality would require 
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